Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.50), $0.02 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $2.71 million versus the consensus estimate of $1.25 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.